Latest Breaking News On - Can 3110 - Page 1 : comparemela.com

CAN-3110, an HSV-1 oncolytic viral immunotherapy candidate, has received FDA fast track designation for adult patients with recurrent high-grade glioma.

United statesAntonio chioccaHarvard medical schoolDepartment of neurosurgery at brighamPeter takCandel therapeuticsCan 3110Adult patients with recurrent high grade gliomaPaul peter takBrigham and womens hospital